Greenwich LifeSciences Announces European Approval for Combining Both HLA Populations in FLAMINGO-01
Greenwich LifeSciences announced that the European Medicines Agency has approved combining both HLA-A*02 and non-HLA-A*02 breast cancer patients in the randomized arms of their Phase III FLAMINGO-01 trial evaluating GLSI-100 immunotherapy. This follows similar approval from the FDA in the US, effectively doubling enrollment capacity and statistical…